Evidence map›Paper›PMID 41125576›Full record

ArticleNPJ vaccines2025

Vaccination against Onchocerca volvulus induces IgG-mediated protective immunity dependent on neutrophils and complement.

Nathan M Ryan, Jessica A Hess, Mohini Nakhale, Annabel A Ferguson, William Stump, Sara Belko, Rachel Monane, Robert S Pugliese, Nikolai Petrovsky, Benjamin L Makepeace and 4 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nathan M RyanDepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Jessica A HessDepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Mohini NakhaleDepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Annabel A FergusonDepartment of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.
William StumpDepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Sara BelkoHealth Design Lab, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Rachel MonaneHealth Design Lab, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Robert S PuglieseHealth Design Lab, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Nikolai PetrovskyVaxine Pty Ltd., Adelaide, SA, Australia.
Benjamin L MakepeaceInstitute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK.
Sean A GrayPAI Life Sciences Inc., Seattle, WA, USA.
Darrick CarterPAI Life Sciences Inc., Seattle, WA, USA.
Sara LustigmanLaboratory of Molecular Parasitology, Lindsey F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
David AbrahamDepartment of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA. david.abraham@jefferson.edu.

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8M
The development of a recombinant vaccine against human onchocerciasisR01AI078314 · NIAID · NEW YORK BLOOD CENTER · PI LUSTIGMAN, SARA · 2009 to 2021
$7.0M
Novel vaccine adjuvants to counter bioterrorist threatsU01AI061142 · NIAID · FLINDERS UNIVERSITY OF SOUTH AUSTRALIA · PI PETROVSKY, NIKOLAI · 2005 to 2009
$3.5M
Phase II - Development of a Prophylactic Onchocerciasis Vaccine75N93019C00028 · NIAID · PAI LIFE SCIENCES, INC. · PI CARTER, DARRICK · 2019 to 2019
$3.0M
NCI NIH HHS P30 CA056036NIAID NIH HHS 75N93019C00028NIAID NIH HHS R01 AI078314NIAID NIH HHS U01 AI061142NIH HHS 75N93019C00028NIH HHS HHS-N272201400053CNIH HHS R01 AI078314
6 · The paper itself

Abstract

Onchocerciasis remains a significant cause of morbidity and economic loss in sub-Saharan Africa. Despite the existence of effective therapeutics, a prophylactic vaccine targeting the etiologic agent, Onchocerca volvulus, is needed to control ongoing disease and transmission. Mice were vaccinated against O. volvulus with a fusion of the recombinant antigens Ov-103 and Ov-RAL-2 (Ov-FUS-1) with Advax-CpG adjuvant. Immunized mice developed protective immunity with the killing of third-stage larvae (L3) within 36 h of challenge infection. IgG from immunized mice passively transferred protective immunity to naïve mice, indicating that antigen-specific IgG mediated parasite elimination. Neutrophils were the most abundant subset of immune cells recruited to the parasite microenvironment in vivo, and treating mice with a granulocyte-depleting antibody resulted in the total loss of immune-mediated larval killing. Analysis of neutrophil gene expression revealed that both vaccination and the presence of O. volvulus larvae were capable of modulating neutrophil transcriptional activity. The mechanism by which antigen-specific IgG and neutrophils collaborated to kill L3 was independent of Fcγ receptors. However, the elimination of complement component C3 prevented vaccine-induced protection, which suggests these components may interact through the complement system. This study describes a vaccine-induced mechanism of protective immunity against O. volvulus L3 dependent on IgG, neutrophils, and complement, highlighting an effective collaboration between the innate and adaptive arms of the immune system to control O. volvulus infection.

Identifiers

PMID41125576
PMCPMC12546713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.